Comparative effectiveness of different drugs used to treat patients in Rheumatoid Arthritis Saudi database (RASD)
The goal of this observational study is to compare the effectiveness of different biological Disease Modifying Antirheumatic Drugs (bDMARDs) and targeted synthetic (tsDMARDs) using Disease Activity Score - 28 joints - C-Reactive Protien (DAS-28-CRP) and Clinical Disease Activity Index (CDAI) scores. In rheumatoid arthritis patients in Saudi Arabia who are part of Rheumatoid Arthritis Saudi Database (RASD).
The main question\[s\] it aims to answer:
* What is the most effective drug (biologocal or targeted synthetic) disease modifying antirheumatic drug used to treat rheumatoid arthritis in Saudi Arabia? * We are going to use two outcome mesures: Disease Activity Score - 28 joints - C-Reactive Protien (DAS-28-CRP) and Clinical Disease Activity Index (CDAI) scores
Researchers will compare the treatment of rheumatoid arthritis using specific outcome measures in Rheumatoid Arthritis in Saudi Arabia.
* Participants will be enrolled after a signed written concent in our Rheumatoid Arthritis Saudi Databas (RASD). * Their treatment data will used to compare the effectiveness of different drugs they are using.
All those patients who are age of 18 years and above and
meeting 2010 American College of Rheumatology classification criteria for rheumatoid arthritis.
Both male and female gender will be included.
There should be minimum of 12 months follow up with at least 3 documented visits of these patients to health care facilities.
Any patient who did not meet the inclusion criteria will be excluded from the study.
Any patient who cannot recall the exact date of starting his drugs will be excluded during data analysis.